Pharmos - Worst Pharma Stocks of 2007

Company: Pharmos
Starting stock price: $1.85
Ending stock price: $0.34
Percent Change: -81.62%

Details: In January of 2007 Pharmos announced that it's Phase II trial of cannabinor, an intravenous therapy for pain, failed to hit its primary endpoint. A separate test for relieving pain associated with molar dental extractions is still ongoing. The company announced that it cut its workforce in Israel by 15--down to 8--in an effort to restructures and conserve cash. Pharmos is also it's considering bringing in new investors to finance the subsidiary as an independent operation.

More News:
Pharmos cuts staff at Israeli subsidiary. Report
Pharmos pain drug fails in Phase II. Report

Pharmos - Worst Pharma Stocks of 2007

Suggested Articles

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

By extending the tender offer for just six days, Roche seems confident it will receive positive reviews from U.S. and U.K. watchdogs in time.

Back in June, Takeda scrapped a Ninlaro trial in rare disease light-chain (AL) amyloidosis. Saturday, it shared the data behind the decision.